AzTrials
AzTrials

Otitis Media With Effusion (OME)NCT07777302

EarFlo: A Non-Invasive Treatment for Otitis Media With Effusion & Eustachian Tube Dysfunction in Adults

A study testing EarFlo Device in people with Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction, run by Philip Perez at 4 sites in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study evaluates the use of the EarFlo device in adults with clinically confirmed Eustachian tube dysfunction and/or otitis media with effusion. The purpose of the study is to assess the safety, tolerability, and short-term effects of device use on ear pressure symptoms and middle ear function. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
EarFlo Device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
4 sitesUnited States
Study dates
27 Aug 2026to 15 May 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 years and older.
  • Adults with confirmed Otitis Media with Effusion (OME) diagnosis with clinical assessment.
  • Adults with confirmed dilatory ETD (Eustachian Tube Dysfunction) on clinical assessment.
  • Willingness to refrain from initiating new treatments for OME/ETD (e.g., new surgical or device treatments, tympanostomy tubes) during the study period. Standard care will not be refrained if needed.

Who cannot join

  • Presence of acute otitis media, ear infection, or otorrhea within the past 4 weeks.
  • Any medical, psychiatric, or cognitive condition that, in the opinion of the investigators, would interfere with study participation or compliance.
  • Inability to use the EarFlo device as instructed (e.g., due to severe nasal obstruction, craniofacial anomalies, or neuromuscular disorders).
  • Recent eye, ear or nose surgeries or ear trauma. (<4 weeks)

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Zarna P Lalwani, BDS, MPH contact

zpl5@pitt.edu

United States4 sites
  • Eye and Ear Institute / UPMC Presbyterian

    Pittsburgh, Pennsylvania, 15213

  • UPMC Montefiore

    Pittsburgh, Pennsylvania, 15213

  • UPMC Mercy

    Pittsburgh, Pennsylvania, 15219

  • UPMC Shadyside

    Pittsburgh, Pennsylvania, 15232

Other trials in United States

About this study

This study evaluates the use of the EarFlo device in adults with clinically confirmed Eustachian tube dysfunction and/or otitis media with effusion. The purpose of the study is to assess the safety, tolerability, and short-term effects of device use on ear pressure symptoms and middle ear function.

Participants will complete a brief symptom questionnaire, undergo routine ear examinations and testing, and use the EarFlo device once during a clinic visit. Ear examination and testing will be repeated after device use to evaluate any short-term changes. This study involves a single study visit and does not include any surgical or invasive procedures.

Read the detailed description

Otitis media with effusion (OME) is a condition characterized by the presence of fluid in the middle ear and may occur in both children and adults. Eustachian tube dysfunction (ETD) is commonly associated with OME and may contribute to symptoms such as ear fullness, pressure, muffled hearing, and discomfort due to impaired ventilation of the middle ear.

The EarFlo device is designed to promote Eustachian tube opening during swallowing. The EarFlo device has been previously evaluated in pediatric populations with otitis media with effusion and is FDA-cleared for its intended use.This study aims to evaluate the safety, tolerability, and short-term effects of the EarFlo device in an adult population diagnosed with OME and/or ETD.

This is a prospective, single-visit, non-randomized interventional study evaluating the safety, tolerability, and short-term effects of the EarFlo device in adults with otitis media with effusion (OME) and/or Eustachian tube dysfunction (ETD). The study focuses on short-term changes in subjective symptoms and objective middle ear findings following a single supervised use of the device in a clinical setting.

Eligible participants will attend one study visit. At baseline, participants will complete a validated symptom questionnaire and undergo routine otologic evaluation, including otoscopic examination and tympanometry, as clinically appropriate. Otoscopic images of the tympanic membrane and middle ear will be captured prior to device use.

Participants will then receive instruction on proper use of the EarFlo device from trained study personnel. The device will be used once during the visit while the participant drinks a liquid of their choice. Device use is noninvasive and does not involve surgical procedures or sedation.

Following device use, participants will repeat middle ear assessments, including tympanometry and otoscopic examination. Post-use otoscopic images will be captured and compared with baseline images. Otoscopic images will be reviewed and categorized as improved or not improved by a physician who is blinded to the timing of image acquisition (pre- or post-device use).

The primary objectives of this study are to evaluate the safety, tolerability, and short-term effects of the EarFlo device in adults and to obtain preliminary estimates of its short-term effects on ear pressure symptoms and middle ear findings following a single supervised use. As a single-arm pilot study, the findings are intended to inform the design of future controlled studies. No long-term follow-up is required.

Being tested
EarFlo Device
Keywords
OME, ETD, Otitis Media with Effusion, Eustachian Tube Dysfunction, EarFlo, Noninvasive Device, Middle Ear Function, Ear Pressure symptoms, autoinflation
Medical subject headings
Otitis Media with Effusion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EarFlo DeviceDevice

    Also called Earflo (Model EF001)

    The EarFlo device is a non-invasive, cup-based device used during swallowing to help equalize middle ear pressure. By delivering a controlled puff of air through the nose during swallowing, it assists Eustachian tube opening to relieve negative middle ear pressure. Participants will use the device once during a single clinic visit while drinking water or a beverage of their choice. No surgery or invasive procedures are involved.

Study groups in NCT07777302
Study groupRoleWhat they receive
EarFlo Intervention ArmExperimentalParticipants in this single arm will undergo baseline assessments, use the EarFlo device once during a clinic visit, and complete post-use assessments to evaluate short-term changes in ear symptoms and middle ear function.
Receives: Device: EarFlo Device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in middle ear pressure and compliance measured by tympanometry following single use of the EarFlo device

    Change in middle ear pressure measured using tympanometric peak pressure (daPa) immediately before and immediately after a single supervised in-clinic use of the EarFlo device. Tympanometric peak pressure values will be compared to evaluate short-term changes in middle ear function. More positive values indicate improved middle ear pressure equalization.

    Measured: Immediately before EarFlo device use (baseline) and immediately after EarFlo device use (post-intervention) during the single study visit

  2. Blinded otoscopic image assessment of middle ear effusion before and after EarFlo device use

    Otoscopic images obtained immediately before and immediately after EarFlo device use will be independently reviewed by a blinded physician. Images will be classified as improved or not improved based on predefined evidence of middle ear effusion and tympanic membrane appearance.

    Measured: Immediately before EarFlo device use (baseline) and immediately after EarFlo device use (post-intervention) during the single study visit

Secondary outcomes (1)
  1. Incidence, severity, and relatedness of adverse events

    Safety and tolerability of the EarFlo device in Adults will be assessed based on the number and percentage of participants experiencing adverse events. Adverse events will be summarized according to incidence, severity, and relationship to the EarFlo device or study procedure.

    Measured: From initiation of EarFlo device use through the end of the single study visit, up to 30 minutes.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Aug 2026
  2. Study start27 Aug 2026 (estimated)
  3. Primary completion30 Nov 2027 (estimated)
  4. Study completion15 May 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single-arm, single-group design. All participants receive the same intervention, that is a single supervised in-clinic use of the EarFlo device. Each participant serves as their own control, with outcomes assessed within-subject by comparing baseline (pre-use) measurements to those obtained immediately after device use. There is no separate control or comparison group.
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07777302
Sponsor's protocol ID
STUDY25050186
Status last verified
Aug 2026
First submitted
21 Jul 2026
Last updated
20 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: There is no current plan to share individual participant data (IPD). Any future data sharing would require separate review and approval and would be conducted in accordance with institutional policies and applicable regulations.

Publications

  • Hura N, Soto MJ, Lalwani Z, Oldakowska I, Oldakowski M, Bumbak P, Santa Maria PL. A novel autoinflation device for persistent pediatric otitis media with effusion: A prospective single-arm cohort study. Am J Otolaryngol. 2026 Jul-Aug;47(4):104862. doi: 10.1016/j.amjoto.2026.104862. Epub 2026 Jun 12.

    PubMed 42296786

Questions about this trial

What is this clinical trial studying?

A study testing EarFlo Device in people with Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction, run by Philip Perez at 4 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Zarna P Lalwani, BDS, MPH (zpl5@pitt.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in middle ear pressure and compliance measured by tympanometry following single use of the EarFlo device (time frame: Immediately before EarFlo device use (baseline) and immediately after EarFlo device use (post-intervention) during the single study visit). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07777302, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in